We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Madrigal Pharmaceuticals Inc
5 own
4 watching
Current Price
$284.88
$3.29
(1.17%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
5,208.48M
52-Week High
322.67
52-Week Low
57.21
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
--
Market Capitalization5,208.48M52-Week High322.6752-Week Low57.21Average Volume0.21MDividend Yield--P/E Ratio--What does the Madrigal Pharmaceuticals Inc do?
Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Read More
How much money does Madrigal Pharmaceuticals Inc make?
News & Events about Madrigal Pharmaceuticals Inc.
Fool.com Headlines
1month ago
Two key tailwinds fueled a surge in the biotech's share price this week.Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by a noteworthy 20% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The ...
Zolmax
1month ago
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) have received a consensus recommendation of Moderate Buy from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has ...
Globe Newswire
3 months ago
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023Madrigal reports year end cash, cash equivalents and marketable securities of $358.8M CONSHOHOCKEN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- ...
Globe Newswire
3 months ago
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor ...
Zolmax
4 months ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) Director Richard S. Levy sold 22,489 shares of the businesss stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $293.15, for a total transaction of $6,592,650.35. Following ...
Frequently Asked Questions
Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc share price today?
Can Indians buy Madrigal Pharmaceuticals Inc shares?
How can I buy Madrigal Pharmaceuticals Inc shares from India?
Can Fractional shares of Madrigal Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Madrigal Pharmaceuticals Inc stocks?
What is today’s traded volume of Madrigal Pharmaceuticals Inc?
What is today’s market capitalisation of Madrigal Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Madrigal Pharmaceuticals Inc?
What percentage is Madrigal Pharmaceuticals Inc down from its 52-Week High?
What percentage is Madrigal Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$284.88
$3.29
(1.17%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.